March 30, 2017 11:21 AM EDT

Takeda chops into Ariad staff, handing out about 180 pink slips as it revamps Boston ops

John Carroll

Editor & Founder

Christophe Weber, president and chief executive officer of Takeda Pharmaceutical Co., speaks during the 18th Nikkei Global Management Forum in Tokyo …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Takeda chops into Ariad staff, handing out about 180 pink slips as it revamps Boston ops

John Carroll

Editor & Founder

Sign up to read this article for free.

Regeneron buys London-based ocular biotech

A look at biotech's year of the megaround

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Roche circles back to China biotech with $80M deal for lung cancer ADC

Neumora's major depression drug flunks first of three Phase 3 trials

Take­da chops in­to Ari­ad staff, hand­ing out about 180 pink slips as it re­vamps Boston ops

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Re­gen­eron buys Lon­don-based oc­u­lar biotech

A look at biotech's year of the megaround

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Takeda chops into Ariad staff, handing out about 180 pink slips as it revamps Boston ops

Regeneron buys London-based ocular biotech

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Roche circles back to China biotech with $80M deal for lung cancer ADC

Neumora's major depression drug flunks first of three Phase 3 trials